'Treatment duration' diaporamas de présentation

Slide Sub-Title

737 views • 65 slides

Infections in the Immunocompromised Host

Infections in the Immunocompromised Host. Rontgene M. Solante, MD, FPCP, FPSMID. Overview. Definitions Diagnostic approach Treatment and prevention of infectious complications Febrile neutropenia Transplant recipients Asplenia HIV/AIDS. Immunocompromised Host.

1.62k views • 57 slides

Iontophoresis

Iontophoresis. Iontophoreis. Introduction of Ions Into The Body Using Direct Electrical Current Transports Ions Across A Membrane Or Into a Tissue It is a Painless, Sterile, Noninvasive Technique Demonstrated To Have A Positive Effect On The Healing Process. Iontophoresis vs Phonophoresis.

789 views • 42 slides

Hepatitis C Overview

Hepatitis C Overview. Introduction . Advocacy & Self-Advocacy through Education The information in this presentation is designed to help you understand and manage HCV and is not intended as medical advice. HCV medical care is a partnership between patients and their medical providers.

490 views • 35 slides

Bayesian posterior predictive probability - what do interim analyses mean for decision making?

Bayesian posterior predictive probability - what do interim analyses mean for decision making?. Oscar Della Pasqua & Gijs Santen Clinical Pharmacology Modelling & Simulation, GlaxoSmithKline, UK Division of Pharmacology, Leiden University, The Netherlands. Time course of HAMD in Depression.

218 views • 21 slides

Cost-Effectiveness Analysis of Raltegravir in Treatment-Experienced HIV Patients in Spain

Cost-Effectiveness Analysis of Raltegravir in Treatment-Experienced HIV Patients in Spain. Mohammad A. Chaudhary, Santiago Moreno, Ritesh N. Kumar, Gonzalo Nocea & Elamin Elbasha. International AIDS Economics Network Symposium Cuernavava, Mexico, August 1-2, 2008. Background.

458 views • 19 slides

Background and Aims

J Bruix, T Poynard, M Colombo, E Schiff, J Reichen, K Burak, EJL Heathcote, T Berg, J-L Poo, C Brandao Mello, R Guenther, C Niederau, R Terg, N Boparai, J Harvey, LH Griffel, M Burroughs, CA Brass, JK Albrecht for the EPIC 3 Study Group.

266 views • 18 slides

Background and Aims

J Bruix, T Poynard, M Colombo, E Schiff, J Reichen, K Burak, EJL Heathcote, T Berg, J-L Poo, C Brandao Mello, R Guenther, C Niederau, R Terg, N Boparai, J Harvey, LH Griffel, M Burroughs, CA Brass, JK Albrecht for the EPIC 3 Study Group.

266 views • 18 slides

Lazarus E 1 ; Otwombe K 1 ; Mohapi L 1 ; Cescon A 2,3 ; Violari A 1 ; Laher F 1

Effect of baseline immunological condition, virological response and duration of HAART on growth in HIV-infected adolescents. Lazarus E 1 ; Otwombe K 1 ; Mohapi L 1 ; Cescon A 2,3 ; Violari A 1 ; Laher F 1

297 views • 17 slides

Responding to Nonresponders: An Experimental Field Trial of Identification and Intervention Methods

Responding to Nonresponders: An Experimental Field Trial of Identification and Intervention Methods. Kristen L. McMaster University of Minnesota Douglas Fuchs, Lynn S. Fuchs, and Donald L. Compton Peabody College of Vanderbilt University. Responsiveness-to-Intervention Symposium

344 views • 16 slides

NNT Analogues When Time Does Matter

NNT Analogues When Time Does Matter. Numbers Needed to Treat Rarely Capture the Temporal Aspects of Therapeutic Efforts J.Hilden @ biostat.ku.dk. ESMDM Rotterdam June 2004.

283 views • 16 slides

NNT Analogues When Time Does Matter

NNT Analogues When Time Does Matter. Numbers Needed to Treat Rarely Capture the Temporal Aspects of Therapeutic Efforts J.Hilden @ biostat.ku.dk. ESMDM Rotterdam June 2004.

168 views • 16 slides

Shortwave Diathermy

1.3k views • 15 slides

The TB paradox

The TB paradox. Massimo Galli L.Sacco Hospital, University of Milano, Italy. The MDR TB challenge.

296 views • 11 slides

Elbasvir-Grazoprevir +/- Ribavirin in HCV Genotype 1, 4 or 6 C-EDGE Treatment Experienced (TE)

Phase 3. Treatment Experienced. Elbasvir-Grazoprevir +/- Ribavirin in HCV Genotype 1, 4 or 6 C-EDGE Treatment Experienced (TE). Source: Kwo P, et al. Gastroenterology. 2017;152:164-75. Elbasvir-Grazoprevir + /- Ribavirin in HCV Genotype 1, 4 or 6 C-EDGE TE Study: Features.

103 views • 10 slides

Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2

Phase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Source: Afdhal N, et al. N Engl J Med. 2014;370:1483-93. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV GT 1 ION-2 Study: Features.

231 views • 9 slides

Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-1

92 views • 9 slides

The Benefits of Advanced Technology in Orthodontics

Advanced technology is helping the world of orthodontics to serve the needs of patients. Receive the best treatment with a reputed orthodontist in Perth.

53 views • 3 slides

Background Information 2 CMT Tight sternocleido-mastoid (SCM) muscle

In infants with congenital muscular torticollis (CMT) does aggressive frequency/duration of physical t herapy impact rate of returning symmetrical cervical range of motion compared to traditional therapy treatment?. Background Information 2 CMT Tight sternocleido-mastoid (SCM) muscle

138 views • 1 slides